Pharma in Argentina: An Interview with Juan Pablo Bagó

Article

Pharmaceutical Executive

2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also  Latin America, with products in  in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.

http://pharmaboardroom.com/interviews/bago-group-juan-pablo-bago-general-director-pharma-argentina/

Recent Videos
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Most Effective Strategies to Close the Innovation Gap in Women’s Health
Root Causes of Innovation Gap in Women’s Health
Fred Aslan
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Related Content
Biogen to Establish New Global HQ and Innovation Hub in Massachusetts by 2028

Biogen to Establish New Global HQ and Innovation Hub in Massachusetts by 2028

Don Tracy, Associate Editor
March 24th 2025
Article

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Stock.adobe.com

Halia Therapeutics Wins Novo Nordisk Golden Ticket

Mike Hollan
March 24th 2025
Article

The biotech won the award for its work in obesity and inflammation treatment.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Pharma Pulse 3/24/25: Boosting Patient Empowerment, Email Remains Leading Security Risk in Healthcare & more

Pharma Pulse 3/24/25: Boosting Patient Empowerment, Email Remains Leading Security Risk in Healthcare & more

Miranda Schmalfuhs
March 24th 2025
Article

The latest news for pharma industry insiders.

FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease

FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease

Don Tracy, Associate Editor
March 21st 2025
Article

Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.